Amber Specialty Pharmacy Begins Dispensing Newly Approved BRINSUPRI™ (brensocatib) for Non-Cystic Fibrosisbronchiectasis (NCFB)

OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy, a pioneer in specialty pharmacy for more than 25 years, today announced it is now dispensing BRINSUPRI™ (brensocatib) following the medication’s U.S. Food and Drug Administration (FDA) approval as the first treatment specifically indicated to reduce pulmonary exacerbations in adults and adolescents with non-cystic fibrosis bronchiectasis, a chronic neutrophil-mediated airway disease.

“Our nationally recognized clinical program is ready to ensure rapid access, personalized counseling, and comprehensive reimbursement support for every patient who needs it,” said Kristin Williams, president of Amber Specialty Pharmacy.

Amber Specialty Pharmacy streamlines the treatment process for both patients and referring providers by offering the following support services:

• Nationwide dispensing through its URAC and ACHC-accredited network
• 24/7 clinical support and adherence counseling from specialty-licensed pharmacists
• End-to-end benefits investigation, prior authorization and financial assistance coordination

Healthcare providers can initiate BRINSUPRI referrals by calling [phone] or visiting amberpharmacy.com/providers/referral-forms to download electronic referral forms.

About Amber Specialty Pharmacy

Amber Specialty Pharmacy is a pioneer in the specialty pharmacy industry, with more than 25 years of experience in providing specialized care for patients with chronic and complex medical conditions. With a focus on personalized support and quality clinical care, Amber Specialty Pharmacy serves patients across the United States. The pharmacy is accredited by both the Utilization Review Accreditation Commission (URAC) and the Accreditation Commission for Health Care (ACHC). Amber Specialty Pharmacy is headquartered in Omaha, Nebraska. To learn more, visit www.amberpharmacy.com.